Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5
1. PODD reported Q2 adjusted earnings of $1.17 per share, beating 92 cents consensus. 2. Sales rose 32.9% year-over-year to $649.1 million, exceeding expectations. 3. U.S. Omnipod revenue grew 28.7%, with international revenue rising 45%. 4. Gross margin increased to 69.7%, showing strong operational efficiency gains. 5. 2025 sales guidance raised to $2.57-$2.63 billion, signaling robust growth potential.